3Kuriyama S,Hozawa A,Ohmori K,et al,Green tea consumption and cognitivefunction:a cross-sectional study from the Tsurugaya Project[J].Am J Clin Nutr,2006,83:355-361.
4Khokhar S,Magnusdottir SG.Total phenol,catechin,and caffeine contents of teascommonly consumed in the United Kingdom[J] J Agric Food Chem.2002.50:565-570.
5Rossi G,Giaccone G,Maletta R.A family with Alzheimer disease and strokesassociated with A713Tmutation of the APP gene[J].Neurolog,2004,63 (5):910-912.
6Gordon MN,Holcomh LA,Jantzen PT.Time of the development of Alzheimer likepathology in the doubly transgenic PSI + APP mouse[J].Exp Neurol,2002,173 (2):183-195.
7Levites Y,Amit T,Mandel S,Youdim MB.Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by,green tea polyphenol (-)-epigallocatechin-3-gallate[J].FASEB J,2003,17 (8):952 - 954.
5Guldenpfennig WM,Poole KH,Sommerville KW,et al.Safety,tolerability,and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.Clin Neuropharmacol,2005,28:106-110.
6Nyholm D,Jansson R,Willows T,et al.Long-term 24-hour duodenal infusion of levodopa:outcome and dose requirements.Neurology,2005,65:1506-1507.
7Konitsiotis S.Novel pharmacological strategies for motor complications in Parkinson's disease.Expert Opin Investig Drugs,2005,14:377-392.
8Hauser RA,Schwarzschild MA.Adenosine A2A receptor antagonists for Parkinson's disease:rationale,therapeutic potential and clinical experience.Drugs Aging,2005,22:471-482.
9Schapira AH.Present and future drug treatment for Parkinson's disease.J Neurol Neurosurg Psychiatry,2005,76:1472-1478.
10Olanow CW,Jankovic J.Neuroprotective therapy in Parkinson's disease and motor complications:a search for a pathogenesistargeted,disease-modifying strategy.Mov Disord,2005,20:S3-S10.
